{"id":24449,"date":"2019-02-12T12:00:00","date_gmt":"2019-02-12T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\/"},"modified":"2019-02-12T12:00:00","modified_gmt":"2019-02-12T12:00:00","slug":"defis-et-strategies-pour-ladoption-des-traitements-biologiques","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/fr\/news\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\/","title":{"rendered":"D\u00e9fis et strat\u00e9gies pour l&#8217;adoption des traitements biologiques"},"content":{"rendered":"<div class=\"paragraph paragraph--text-columns paragraph-id--1469 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<h2>Rhinology Future Debates Bruxelles 2018<\/h2>\n<p>Le Pr Claus Bachert partage des strat\u00e9gies pour l&#8217;adoption du traitement biologique chez les patients atteints de RSCaN et des parcours de soins int\u00e9gr\u00e9s pour la RSC. Il explique \u00e9galement les possibilit\u00e9s de traitement et la d\u00e9finition des patients qui devraient \u00eatre trait\u00e9s par anticorps monoclonaux. <\/p>\n<h3>Intervenants<\/h3>\n<p>Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, repr\u00e9sentants des patients.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"paragraph paragraph--text-columns paragraph-id--1470 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<div class=\"video-container\"><center><iframe title=\"Lecteur vid\u00e9o YouTube\" src=\"https:\/\/www.youtube.com\/embed\/oKJ506sZiAY?rel=0\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/center><\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Rhinology Future Debates Bruxelles 2018 Le Pr Claus Bachert partage des strat\u00e9gies pour l&#8217;adoption du traitement biologique chez les patients atteints de RSCaN et des parcours de soins int\u00e9gr\u00e9s pour la RSC. Il explique \u00e9galement les possibilit\u00e9s de traitement et la d\u00e9finition des patients qui devraient \u00eatre trait\u00e9s par anticorps monoclonaux. Intervenants Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, repr\u00e9sentants des patients.<\/p>\n","protected":false},"author":1,"featured_media":24459,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[189],"tags":[191,192,194,170,174,175,190],"class_list":["post-24449","news","type-news","status-publish","has-post-thumbnail","hentry","category-rhinology-future-debates","tag-debats","tag-rhinology-future-debates","tag-rhinosinusite-chronique-rsc","tag-professionnels-de-sante","tag-crswnp","tag-biotherapies","tag-rhinologie"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>D\u00e9fis et strat\u00e9gies pour l&#039;adoption des traitements biologiques - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/fr\/news\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"D\u00e9fis et strat\u00e9gies pour l&#039;adoption des traitements biologiques\" \/>\n<meta property=\"og:description\" content=\"Rhinology Future Debates Bruxelles 2018 Le Pr Claus Bachert partage des strat\u00e9gies pour l&#8217;adoption du traitement biologique chez les patients atteints de RSCaN et des parcours de soins int\u00e9gr\u00e9s pour la RSC. Il explique \u00e9galement les possibilit\u00e9s de traitement et la d\u00e9finition des patients qui devraient \u00eatre trait\u00e9s par anticorps monoclonaux. Intervenants Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, repr\u00e9sentants des patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/fr\/news\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\\\/\",\"name\":\"D\u00e9fis et strat\u00e9gies pour l'adoption des traitements biologiques - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202018_16.png\",\"datePublished\":\"2019-02-12T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202018_16.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202018_16.png\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/choisissez-votre-parcours\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"D\u00e9fis et strat\u00e9gies pour l&#8217;adoption des traitements biologiques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"D\u00e9fis et strat\u00e9gies pour l'adoption des traitements biologiques - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/fr\/news\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\/","og_locale":"fr_FR","og_type":"article","og_title":"D\u00e9fis et strat\u00e9gies pour l'adoption des traitements biologiques","og_description":"Rhinology Future Debates Bruxelles 2018 Le Pr Claus Bachert partage des strat\u00e9gies pour l&#8217;adoption du traitement biologique chez les patients atteints de RSCaN et des parcours de soins int\u00e9gr\u00e9s pour la RSC. Il explique \u00e9galement les possibilit\u00e9s de traitement et la d\u00e9finition des patients qui devraient \u00eatre trait\u00e9s par anticorps monoclonaux. Intervenants Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, repr\u00e9sentants des patients.","og_url":"https:\/\/www.euforea.org\/fr\/news\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","twitter_card":"summary_large_image","twitter_site":"@euforea","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/fr\/news\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\/","url":"https:\/\/www.euforea.org\/fr\/news\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\/","name":"D\u00e9fis et strat\u00e9gies pour l'adoption des traitements biologiques - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/fr\/news\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/fr\/news\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202018_16.png","datePublished":"2019-02-12T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/fr\/news\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/fr\/news\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/fr\/news\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202018_16.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202018_16.png","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/fr\/news\/defis-et-strategies-pour-ladoption-des-traitements-biologiques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.euforea.org\/fr\/choisissez-votre-parcours\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/fr\/news\/"},{"@type":"ListItem","position":3,"name":"D\u00e9fis et strat\u00e9gies pour l&#8217;adoption des traitements biologiques"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/fr\/#website","url":"https:\/\/www.euforea.org\/fr\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/fr\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/24449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/comments?post=24449"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/24449\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media\/24459"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media?parent=24449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/categories?post=24449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/tags?post=24449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}